Pre-market Hot Trades in US Stocks

Nebius is down 4.14% in pre-market trading. Based on recent key news:

1. On July 25, Nebius's stock price fell 10.26% to $198.30, approaching a key support level of $200.50. Buyers had previously been active near this support level, and the price drop may be related to market concerns about the demand for AI infrastructure. Source: Benzinga

2. On July 27, Nebius focused on leasing AI computing power. Despite the demand for AI infrastructure continuing to exceed supply, many investors remain cautious due to its volatility and lack of profitability. Source: MarketBeat

3. On July 28, Nebius received strong support from Nvidia, with expectations of significant revenue growth over the next three years. However, as its influence expands, the risks it faces are also increasing. Source: MarketBeat AI infrastructure demand is strong, and market volatility is intensifying.

Astera Labs is down 4.08% in pre-market trading. Based on recent key news:

1. On July 27, market analysis showed that Astera Labs was not included in the top five stocks recommended by leading analysts, although it is currently rated as a moderate buy. This information may lead to a decline in investor confidence, affecting the stock price.

2. On July 27, Astera Labs's stock price showed an increase of 1.88% in Benzinga Pro data, but overall market sentiment may negatively impact its pre-market performance.

3. On June 29, UBS raised Astera Labs's target price to $205 while maintaining a neutral rating. Despite the target price increase, the rating remained unchanged, which may not effectively boost market confidence. Market sentiment is volatile, with attention on macroeconomic dynamics.

Top Gainers in Pre-market US Stocks

C3is is up 103.81% in pre-market trading. Based on recent key news:

1. On July 27, C3is announced a public offering at a price of $0.52 per unit, with expected total proceeds of approximately $6 million. This move has enhanced market confidence in the company's liquidity, driving the stock price up. Source: Reuters

2. On July 25, C3is executed a 1-for-7 reverse stock split to regain compliance and expand its fleet, with adjusted net income soaring 358% to $5.5 million in the first quarter. This financial performance has raised investor expectations for the company's growth potential. Source: Zhito Finance

3. On July 27, C3is registered a statement with the SEC to enter the US capital market, financing its operations and growth plans through equity and warrant structures. This move further solidifies the company's position in the capital market. Source: Reuters The shipping industry has recently performed strongly, with significant capital inflows Inlif pre-market rose 40.85%. Based on recent key news:

4. On July 24, the Securities and Exchange Commission announced that Inlif received important approval, driving a significant increase in stock price. The announcement indicated that the company made progress on key projects, enhancing market confidence, which led to a pre-market increase of 40.85% in stock price;

5. On July 25, the European Investment Bank announced a delay in loan payments to Brenmiller Energy, alleviating market concerns about the company's financial pressure, indirectly affecting the performance of related industry stocks;

6. On July 28, SK Telecom and United Microelectronics Corp saw their stock prices drop by 9.8% and 7.2%, respectively, as overall market sentiment towards tech stocks weakened, impacting investor confidence in related sectors. Tech stocks have shown volatility recently, and caution is advised for investments.

Gossamer Bio pre-market rose 38.26%. Based on recent key news:

1. On July 27, Gossamer Bio announced positive progress in its Pre-NDA meeting with the FDA, planning to submit a new drug application for seralutinib in September 2026. This news drove the stock price up.

2. On July 27, the company's shareholders approved a proposal for the exchange of convertible notes and a reverse stock split, aimed at optimizing the capital structure. This move enhanced market confidence and further boosted the stock price.

3. On July 28, the company announced a reduction of approximately $115.9 million in debt principal, bringing the remaining balance of the 2027 notes down to $18.9 million. This news improved the financial situation and lifted the stock price. The biopharmaceutical industry has shown strong performance recently, with significant capital inflows